Neurofibromatosis: Clinical and Genetic Findings
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 619
Special Issue Editors
Interests: neurofibromatosis; pediatrician; epidemiology; guideline
Interests: genetics; immunology; cancer
Special Issue Information
Dear Colleagues,
Background and importance
Neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (NF2), and non-NF2-related schwannomatosis (SWN) are rare genetic disorders predisposing to the development of various tumors of the central and peripheral nervous systems. Although often benign, these neoplasms can still cause significant morbidity due to their size and/or location and are rarely amenable to surgical resection. It is therefore essential to translate pre-clinical advances into more effective treatment options for many of these tumors. To position these treatments, it is essential to understand the natural course, disease modifiers, and biomarkers. Finally, we are in need of a wider consensus on the preferred main outcomes of these potential treatments, including neurologic morbidity, vision, and ultimately, daily functioning and quality of life.
Goals
In this Special Issue of Cancers, we welcome original research articles and comprehensive review articles focusing on the disease course, disease modifiers, and treatments of tumors in patients with neurofibromatosis type 1, NF2-related schwannomatosis, and non-NF2-related schwannomatosis, aiming for significant advancements in this challenging yet fascinating field.
Dr. Rianne Oostenbrink
Dr. Ignaci Blanco
Dr. Enrico Opocher
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurofibromatosis
- schwannomatosis
- tumor
- longitudinal history
- treatment
- biomarker
- outcomes
